ArticleCancer reports (Hoboken, N.J.)2026
Postoperative Adjuvant Chemoradiotherapy ± PD-1 Inhibitor for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Zhiqiang Wang, Qingqing He, Donghui Jiang, Sheng Cheng, Jingyu Gao, Yan Wang, Shuai Fu, Qing Ying Cui, Yanli Yang, Li Lv and 5 more
Abstract read
In one paragraphArticle in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Zhiqiang WangDepartment of Radiotherapy Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.ORCID 0000-0002-2490-320X Qingqing HeDepartment of Radiotherapy Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.ORCID 0009-0002-6974-4414 Donghui JiangDepartment of 2nd Otorhinolaryngology, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.ORCID 0009-0004-7610-5666 Sheng ChengDepartment of 1st Otorhinolaryngology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.ORCID 0009-0003-7781-6446 Jingyu GaoDepartment of 1st Otorhinolaryngology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.ORCID 0000-0002-7480-5616 Yan WangDepartment of 1st Otorhinolaryngology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.ORCID 0000-0002-6152-8007 Shuai FuDepartment of Oral and Maxillofacial Surgery, Kunming Medical University School and Hospital of Stomatology, Kunming, China.ORCID 0009-0002-6899-7268 Qing Ying CuiDepartment of Oral and Maxillofacial Surgery, Kunming Medical University School and Hospital of Stomatology, Kunming, China.ORCID 0000-0002-9408-7498 Yanli YangDepartment of 1st Otorhinolaryngology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.ORCID 0009-0007-0593-1604 Li LvDepartment of Medical Oncology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.ORCID 0000-0002-0339-862X Yuchuan XuDepartment of Radiotherapy Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.ORCID 0009-0009-8984-9812 Yan LiDepartment of Radiotherapy Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.ORCID 0000-0002-9897-5548 Rui TianDepartment of Radiotherapy Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.ORCID 0009-0006-2645-8468 Chunlei GeDepartment of Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, People's Republic of China.ORCID 0000-0001-8393-8341 Rongqing LiDepartment of Radiotherapy Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.ORCID 0000-0003-1501-6171 Funding
Doctoral Research Start-up Fund for First Affiliated Hospital of Kunming Medical University 2021BS005National Natural Science Foundation of China 82260462National Natural Science Foundation of China 82460606Precision Radiotherapy Science and Technology Innovation Team of Yunnan Universities K12322113t535 Talent Project of First Affiliated Hospital of Kunming Medical University 2023535Q05Yunnan Fundamental Research Kunming Medical University Projects 202301AY070001-115Yunnan Fundamental Research Projects 202301AT070130Yunnan Health Training Project of High Level Talents H-202423
6 · The paper itselfAbstract
backgroundPostsurgical immunotherapy for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) remains elusive. This study assesses the value and significance of postoperative immunotherapy in the treatment of locally advanced HNSCC.
methodsIn total, 212 patients with locally advanced HNSCC who underwent radical surgery were stratified into three treatment groups: adjuvant radiotherapy alone, adjuvant chemoradiotherapy (CRT), and adjuvant chemoradiotherapy plus immunotherapy (PD-1 Ab). A comprehensive analysis was conducted to assess survival outcomes and prognostic factors across diverse patient cohorts.
resultsFour patients were lost to follow-up, with a follow-up rate of 98.1% and a median follow-up time of 41 months (IQR 24-68). A total of 64/212 individuals died, with cancer being the cause of 62 cases and noncancer causes accounting for the remaining two deaths; 62/212 (29.2%) patients experienced relapse and/or metastasis. The 3-year OS rates for the radiotherapy group, CRT group, and CRT plus PD-1 Ab group were 54.8%, 75.4%, and 82.2%, respectively. However, no statistically significant difference in OS or PFS was observed between the CRT and CRT + PD-1 Ab groups (p
conclusionPD-1 Ab may contribute less to tumors with better treatment outcomes from concurrent chemoradiotherapy.
Indexed as
Chemoradiotherapy, AdjuvantHead and Neck NeoplasmsImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisProgrammed Cell Death 1 ReceptorRetrospective StudiesImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptoradjuvant therapyhead and neck squamous cell carcinomaintensity‐modulated radiation therapyPD‐1 Abpostsurgical immunotherapy
Identifiers
PMID41758071
PMCPMC12947766
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390